Park Ha Biological Technology (BYAH) Common Equity (2023 - 2026)

Park Ha Biological Technology (BYAH) has reported Common Equity for 4 consecutive years, with $5.4 million the latest figure, recorded in Q2 2026.

• Quarterly Common Equity rose 26.75% year-over-year to $5.4 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $5.4 million (up 26.75% YoY) and the FY2025 annual result came in at $4.0 million, up 165.25% from the prior year.
• Common Equity improved to $5.4 million in Q2 2026 per BYAH's latest filing, from $4.0 million in the prior quarter.
• Over the last five years, Common Equity for BYAH reached as high as $5.4 million in Q2 2026 and fell as low as $1.0 million in Q4 2023.
• A 4-year average of $3.2 million and a median of $4.0 million in 2025 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2025 — Common Equity jumped 165.25% — and 2026, when it increased 26.75%.
• Year by year, Common Equity stood at $1.0 million in 2023, then surged by 48.75% to $1.5 million in 2024, then soared by 165.25% to $4.0 million in 2025, then soared by 34.86% to $5.4 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $5.4 million, $4.0 million, and $4.3 million for Q2 2026, Q4 2025, and Q2 2025 respectively.